Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Thera SolutionsSHSE:688177 +0.81%58 PB Ratio is 58.23 as of Sep. 08, 2026, which is 561% above its 10-year median of 8.81. GuruFocus rates SHSE:688177 with a GF Score™ of 58/100 and a GF Value™ of ¥33.23 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,217 Biotechnology companies, Bio-Thera Solutions ranks worse than 97.95% on this metric.
The historical rank and industry rank for Bio-Thera Solutions's PB Ratio or its related term are showing as below:
SHSE:688177'
s PB Ratio Range Over the Past 10 Years
Min: 3.8 Med: 8.81 Max: 73.18
Current: 58.03
During the past 10 years, Bio-Thera Solutions's highest PB Ratio was 73.18. The lowest was 3.80. And the median was 8.81.
SHSE:688177's PB Ratio is ranked worse than 97.95% of 1217
companies
in the Biotechnology industry
Industry Median: 3.02
vs SHSE:688177: 58.03
During the past 12 months, Bio-Thera Solutions's average Book Value Per Share Growth Rate was -78.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -38.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -28.80% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Bio-Thera Solutions was 70.20% per year. The lowest was -38.40% per year. And the median was 5.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bio-Thera Solutions PB Ratio Related Terms
Bio-Thera Solutions PB Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Thera Solutions's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688177 vs VRTX, REGN, MRNA: PB Ratio Comparison
For the Biotechnology subindustry, Bio-Thera Solutions's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Thera Solutions PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Thera Solutions's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Thera Solutions's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bio-Thera Solutions (SHSE:688177) has a PB Ratio of 58.23 as of Sep. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Thera Solutions and its competitors. This is 561% above median its historical median of 8.81. Over the past decade, Bio-Thera Solutions' PB Ratio has ranged from 3.80 to 73.18. According to the industry distribution chart, Bio-Thera Solutions ranks #1192 out of 1217 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Bio-Thera Solutions' PB Ratio too high?
Bio-Thera Solutions' current PB Ratio of 58.23 is 561% above median its 10-year median of 8.81. Over the past 10 years, this metric has ranged from a low of 3.80 to a high of 73.18. The Biotechnology industry median PB Ratio is 3.02. Bio-Thera Solutions' value of 58.23 is 1828.1% above this industry median. Based on the distribution chart, Bio-Thera Solutions ranks #1192 out of 1217 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Bio-Thera Solutions has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio-Thera Solutions' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Thera Solutions ranks #1192 out of 1217 companies for PB Ratio. This places Bio-Thera Solutions in the lower half of its industry. The industry median PB Ratio is 3.02. Bio-Thera Solutions' value of 58.23 is 1828.1% above this benchmark. Historically, Bio-Thera Solutions' own PB Ratio has ranged from 3.80 to 73.18 over the past decade. While the company's 10-year median is 8.81 vs. the industry median of 3.02, Bio-Thera Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 3.02, based on 1,217 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Thera Solutions's current PB Ratio of 58.23 is 1828.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bio-Thera Solutions and its competitors. For the Biotechnology industry, the median PB Ratio is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Thera Solutions's current PB Ratio is 58.23, which is 561% above median its own 10-year median of 8.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Thera Solutions stock overvalued right now?
Based on GuruFocus' analysis, Bio-Thera Solutions (SHSE:688177) is currently considered Possible Value Trap. The stock's GF Value™ is ¥33.23, compared to a current price of ¥17.41 — trading 47.6% below its estimated fair value. The current PB Ratio is 58.23, which is 561% above median its 10-year median of 8.81 and 1828.1% above the Biotechnology industry median of 3.02. Bio-Thera Solutions' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bio-Thera Solutions (SHSE:688177), the current PB Ratio is 58.23 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Thera Solutions (SHSE:688177) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Thera Solutions stock appears to be undervalued.
The current stock price of ¥17.41 is trading 47.6% below its estimated GF Value™ of ¥33.23.
GuruFocus considers Bio-Thera Solutions to be Possible Value Trap.
Key valuation signals for SHSE:688177:
PB Ratio: 58.23 (561% above median its 10-year median of 8.81)
GF Value™: ¥33.23 vs. price of ¥17.41 (47.6% below fair value)
Industry Position: 1828.1% above the Biotechnology median (#1192 of 1217)
No single metric tells the full story. See the SHSE:688177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
58GF Score
Get the complete analysis for SHSE:688177
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688177 has been successfully added to your 
